Reply to 'development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2' by Solimani F et al.

Falcinelli, F; Lamberti, A; Cota, C; Rubegni, P; Cinotti, E

Falcinelli, F; Lamberti, A; Cota, C; Rubegni, P; Cinotti, E.

Afiliação

Falcinelli F; Dermatology Unit and Skin Bank, Department of Medical, Surgical and Neurosciences, Siena University Hospital, Siena, Italy.
Lamberti A; Dermatology Unit and Skin Bank, Department of Medical, Surgical and Neurosciences, Siena University Hospital, Siena, Italy.
Cota C; Dermatopathology Unit, San Gallicano Dermatological Institute, IRCCS, Rome, Italy.
Rubegni P; Dermatology Unit and Skin Bank, Department of Medical, Surgical and Neurosciences, Siena University Hospital, Siena, Italy.
Cinotti E; Dermatology Unit and Skin Bank, Department of Medical, Surgical and Neurosciences, Siena University Hospital, Siena, Italy.

J Eur Acad Dermatol Venereol ; 36(12): e976-e978, 2022 12.

Article em En | MEDLINE | ID: mdl-35789506

Assuntos

COVID-19; Pênfigo; Humanos; Vacina BNT162; Vacinas contra COVID-19/efeitos adversos; SARS-CoV-2; COVID-19/prevenção & controle; Vacinação/efeitos adversos; Anticorpos Antivirais

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pênfigo / COVID-19 Limite: Humans Idioma: En Revista: J Eur Acad Dermatol Venereol Assunto da revista: DERMATOLOGIA / DOENCAS SEXUALMENTE TRANSMISSIVEIS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google